Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Sun Yat-sen University

Status and phase: Completed; Phase 4

Conditions: Gastric Cancer After D2 Lymph Node Dissection

Treatments: Drug: Somatostatin

Study type: Interventional

Funder types: Other

Identifiers

NCT01914692

nova-0426

Details and patient eligibility

About

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Enrollment: 2 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. More than eighteen years old
2. Gastric cancer diagnosed by pathological examination
3. Be given informed consent
4. Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency

Exclusion criteria

1. Contraindication of vascular puncture operation
2. Patients who refused to take part in the programe
3. Poor compliance of treatment
4. Malnutrition,BMI<18
5. with pancreatectomy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

2 participants in 2 patient groups, including a placebo group

Somatostatin group

Experimental group

Description:

Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.

Treatment:

Drug: Somatostatin

Blank group

Placebo Comparator group

Description:

Use the normal saline instead of somatostatin.